Vaccine News and Research

Latest Vaccine News and Research

California and Texas took different routes to vaccination. Who’s ahead?

California and Texas, the country's two most populous states, have taken radically different approaches to the pandemic and the vaccination campaign to end it.

22 Apr 2021

Cleaning frequency key to limiting SARS-CoV-2 spread at theme parks

A new preprint research paper provides some insights into how this may be done using computational modeling. The study, which appeared on the medRxiv server, deals with the mitigation strategies that must be implemented in order to contain the virus.

22 Apr 2021

B.1.1.7 variant 45% more infectious than wild-type SARS-CoV-2, but can be effectively contained by BNT162b2 vaccine

The SARS-CoV-2 B.1.1.7 variant, also called the UK variant, was identified in London as well as in Southeast and East of England in December 2020. Since its emergence, the UK variant has undergone several mutations that have been said to have altered its infectivity and transmissibility in the community. The B.1.1.7 variant is defined by 17 mutations, several of which are located in the SARS-CoV-2 spike protein that mediates viral attachment and entry into human cells.

21 Apr 2021

SARS-CoV-2 vaccine with single-cycle adenovirus vector

Researchers in the United States have developed adenovirus vectors that may be more effective at generating immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than those used in the vaccines that are currently being rolled out to help combat the coronavirus disease 2019 (COVID-19) pandemic.

21 Apr 2021

Argonne's Advanced Photon Source guided the development of new COVID-19 vaccine now in trials

Human clinical trials have begun on a new vaccine candidate that may protect against not only SARS-CoV-2, the virus that causes COVID-19, but against at least two of the variants emerging around the world.

21 Apr 2021

SARS-CoV-2 infection induces polyfunctional antibodies that can destroy infected cells

Drawing on epidemiological field studies and the FrenchCOVID hospital cohort coordinated by Inserm, teams from the Institut Pasteur, the CNRS and the Vaccine Research Institute (VRI, Inserm/University Paris-Est Créteil) studied the antibodies induced in individuals with asymptomatic or symptomatic SARS-CoV-2 infection.

21 Apr 2021

Immune escape by SARS-CoV-2 mutations acquired in mink

A new study, published in Cell Reports, suggests that SARS-CoV-2 may have acquired such immune evasion mutations during its transmission in farmed mink.

21 Apr 2021

FDA takes steps to ensure that COVID-19 vaccines meet high standards for quality, safety and effectiveness

The U.S. Food and Drug Administration takes its responsibility to ensure medical product quality, safety and effectiveness very seriously.

21 Apr 2021

Censorship or misinformation? Desantis and YouTube spar over Covid roundtable takedown.

In early April, YouTube took down a video featuring Florida Gov. Ron DeSantis and a group of controversial scientists at a March 18 coronavirus roundtable. The online video platform, owned by Google, cited as its rationale that the video contained false statements about the efficacy of children's mask-wearing.

21 Apr 2021

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

21 Apr 2021

Antibody response induced by mRNA vaccination differs from natural SARS-CoV-2 infection

Researchers tested the antibodies elicited from mRNA vaccination and compared them to those from natural SARS-CoV-2 infection. They found the vaccine did not have antibodies to the virus nucleocapsid protein but had potent RBD antibodies.

21 Apr 2021

Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2

A new study led by Hans-Martin Jäck of the Friedrich-Alexander University Erlangen-Nuremberg in Germany engineered clusters of neutralizing monoclonal antibodies using a transgenic mouse model. A unique characteristic for the antibodies was the different ways it bound to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the overall reduction in the viral spread for human ACE2.

21 Apr 2021

Seroprevalence studies monitoring SARS-CoV-2 among vaccinees require more than spike assays

Researchers in the United States have shown that an antibody test measuring host reactivity to the nucleocapsid protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may better detect natural infection among vaccinated individuals than an assay that measures reactivity to the viral spike protein.

21 Apr 2021

Children develop strong, long-lasting immunity following SARS-CoV-2 infection

Researchers in the UK have conducted a study that may explain why children who become infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) do not generally develop severe coronavirus disease 2019 (COVID-19).

20 Apr 2021

Study explores how lessons from past crises could improve the pandemic response

The lack of accountability, poor communication and insufficient planning plaguing the government’s response to the COVID-19 pandemic -- especially in its early months -- have roots in how the nation responded to 9/11, Hurricane Katrina and the H1N1 swine flu, a new study involving the University of Washington found.

20 Apr 2021

Chronic SARS-CoV-2 infections favor viral adaptation, says study

A new study offers a look at how to keep these hopes alive in the current context of highly infectious variants, which often display immune escape mutations.

20 Apr 2021

Humoral immunity developed by DNA vaccine INO-4800 is effective against SARS-CoV-2 variants

A team of international scientists recently demonstrated that antibodies generated in response to the DNA vaccine INO-4800 can effectively neutralize some of the recently emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), such as G614, 501Y.V1, and 501Y.V2.

20 Apr 2021

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

To monitor antibody level duration of vaccine-induced immune responses, a team of researchers in the U.S. – at Diacarta, University of California and VA Healthcare System, and the Franciscan University of Steubenville – evaluated the feasibility of using a single drop of fingerstick blood collected with flocked swabs for quantitative antibody response evaluation after COVID-19 vaccination.

20 Apr 2021

Could virosome-based nanovaccines be a promising new approach to preventing viral diseases?

A recent review in the International Journal of Biological Macromolecules provides a novel overview of 'virosome'-based nanovaccine production, its properties, and its application in viral diseases, emphasizing its importance in SARS-CoV-2 vaccine discovery.

20 Apr 2021

Gut's immune response in COVID-19 patients may not provide adequate protection to other organs

Our guts may not provide long-lasting systemic immunity from COVID-19, which is where immune cells circulate through the body to provide protection to other organs, finds a new study published in Frontiers in Immunology.

20 Apr 2021

Vaccine News and Research

Latest Vaccine News and Research

California and Texas took different routes to vaccination. Who’s ahead?

Cleaning frequency key to limiting SARS-CoV-2 spread at theme parks

B.1.1.7 variant 45% more infectious than wild-type SARS-CoV-2, but can be effectively contained by BNT162b2 vaccine

SARS-CoV-2 vaccine with single-cycle adenovirus vector

Argonne's Advanced Photon Source guided the development of new COVID-19 vaccine now in trials

SARS-CoV-2 infection induces polyfunctional antibodies that can destroy infected cells

Immune escape by SARS-CoV-2 mutations acquired in mink

FDA takes steps to ensure that COVID-19 vaccines meet high standards for quality, safety and effectiveness

Censorship or misinformation? Desantis and YouTube spar over Covid roundtable takedown.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

Antibody response induced by mRNA vaccination differs from natural SARS-CoV-2 infection

Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2

Seroprevalence studies monitoring SARS-CoV-2 among vaccinees require more than spike assays

Children develop strong, long-lasting immunity following SARS-CoV-2 infection

Study explores how lessons from past crises could improve the pandemic response

Chronic SARS-CoV-2 infections favor viral adaptation, says study

Humoral immunity developed by DNA vaccine INO-4800 is effective against SARS-CoV-2 variants

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

Could virosome-based nanovaccines be a promising new approach to preventing viral diseases?

Gut's immune response in COVID-19 patients may not provide adequate protection to other organs

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in